Cabotegravir/rilpivirine (Cabenuva) vs Dapivirine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Cabotegravir/rilpivirine (Cabenuva)

Marketed by GlaxoSmithKline

Approved in HIVsmall molecule
Weak signal

NCT05917509 · Phase 3 · completed

The 171 participants were assigned to active treatment groups without randomization or blinding, which limits the reliability of comparisons between the regimens. The primary outcomes measured virologic suppression. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: March 2027 · NCT06411223 (registry estimate)

Reported efficacy

Percentage of Participants With Plasma Human Immunodeficiency Virus-ribonucleic Acid (HIV-RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Week 48: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). (met)

Result source: NCT03299049

Dapivirine · Dapivirine Vaginal Ring

Marketed by Population Council and partners

Phase 3 in HIVsmall molecule
Reliable signal

NCT01617096 · Phase 3 · completed

This Phase 3 trial randomized 2,629 women to a monthly dapivirine vaginal ring or a placebo ring, with participants and investigators blinded, and used HIV-1 seroconversion as the primary endpoint. The published analysis shows a 27% lower incidence of HIV-1 infection with dapivirine (95% CI 1 to 46; P = 0.046). The design is robust and the primary comparison is statistically significant, although the effect was smaller where adherence was low.

Reported efficacy

Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial. (minimum of 12 months and a maximum of 14 months per participant); The Number of Participants That Experienced Grade 2, 3, 4 and Serious Adverse Events Over the Investigational Product Used Period (25 mg Dapivirine Administered in a Silicone Elastomer Vaginal Matrix Ring (DVR), Inserted Once Every 4 Weeks). (minimum of 12 months and a maximum of 14 months per participant): HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007). (met)

Result source: NCT01617096

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointCabotegravir/​rilpivirine (Cabenuva)Dapivirine
HIV-1 RNA below 50 copies/mL (week 48)94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
—Trial running · NCT06250504
HIV-1 RNA 50 copies/mL or more (week 48)0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT03639311—Trial running · NCT06250504
CD4 count, change (week 48)270.6 vs 369.9vs CAB 30 mg+ABC/3TCIM-Q4W · wk 96 · n 108NCT02120352
36 other results
  • 263.7 vs 346.1 IM-Q4W · wk 32 · n 108 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
—Trial running · NCT06250504

HIV-1 RNA below 50 copies/mL (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
Dapivirine
—Trial running · NCT06250504

HIV-1 RNA 50 copies/mL or more (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT03639311
Dapivirine
—Trial running · NCT06250504

CD4 count, change (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
270.6 vs 369.9vs CAB 30 mg+ABC/3TCIM-Q4W · wk 96 · n 108NCT02120352
36 other results
  • 263.7 vs 346.1 IM-Q4W · wk 32 · n 108 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
Dapivirine
—Trial running · NCT06250504
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Cabotegravir/rilpivirine (Cabenuva): 4 of 4 rows · Dapivirine: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCabotegravir/​rilpivirine (Cabenuva)Dapivirine
Dropout rate
13.6%a
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
8.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
13.1%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
6.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
11.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
1.3%CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
15.6%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
11.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
13.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
15.2%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
11.3%25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
9.9%25 mg
NCT02862171 · Phase 3
3.6%25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
—
NCT03593655 · Phase 2 · registry result, not featured evidence
5.5%
NCT02028338 · Phase 2 · registry result, not featured evidence
2.8%
NCT02010593 · Phase 2 · registry result, not featured evidence
20.9%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
23.3%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
10.5%
NCT03239483 · Phase 1 · registry result, not featured evidence
31%
NCT01539226 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—a
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
5.7%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
3.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
4.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
1.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
1.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
4.9%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
—25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
—25 mg
NCT02862171 · Phase 3
—25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
—
NCT03593655 · Phase 2 · registry result, not featured evidence
—
NCT02028338 · Phase 2 · registry result, not featured evidence
—
NCT02010593 · Phase 2 · registry result, not featured evidence
4.7%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
—
NCT03239483 · Phase 1 · registry result, not featured evidence
0%
NCT01539226 · Phase na · registry result, not featured evidence
Serious AEs
0%a
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
3.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
6.3%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
3.4%Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
4%
NCT04399551 · Phase 3 · registry result, not featured evidence
7.8%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
12.7%Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
10%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
26.5%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
11.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
0%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.4%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
17%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.1%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.6%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
15.2%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
12.5%Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
7.1%300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
8.8%25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
2.1%25 mg
NCT02862171 · Phase 3
1.4%25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
0%
NCT03593655 · Phase 2 · registry result, not featured evidence
2.7%
NCT02028338 · Phase 2 · registry result, not featured evidence
1.4%
NCT02010593 · Phase 2 · registry result, not featured evidence
2.3%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%
NCT03239483 · Phase 1 · registry result, not featured evidence
3.1%
NCT01539226 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
injection site discomfort 13.6%
injection site pain 13.6%
fatigue 2.3%
NCT04982445 · Phase 4 · registry result, not featured evidence
show 40 more results
400 mg + 600 mg Q4W
injection site pain 32.3%
injection site nodule 9.7%
injection site induration 2.2%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 74.2%
injection site nodule 64.5%
injection site erythema 51.6%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 30.9%
injection site nodule 3.2%
injection site pruritus 2.1%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
injection site pain 65.2%
covid-19 17.9%
headache 12.5%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 60.6%
covid-19 19.4%
injection site induration 11.4%
NCT04542070 · Phase 3 · registry result, not featured evidence
Q2M
injection site pain 37.9%
covid-19 14.5%
arthralgia 0%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 80.2%
covid-19 18.4%
injection site induration 11.2%
NCT04399551 · Phase 3 · registry result, not featured evidence
injection site pain 55.7%
injection site discomfort 26.1%
fatigue 20%
NCT04001803 · Phase 3 · registry result, not featured evidence
creatinine renal clearance decreased 19.7%
lipase increased 11.3%
chills 7%
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 99.1%
injection site nodule 49.6%
nasopharyngitis 47%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 80%
injection site nodule 50%
nasopharyngitis 50%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 96.5%
nasopharyngitis 47%
injection site nodule 40%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 91.2%
injection site nodule 35.3%
covid-19 26.5%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
Q2M
injection site pain 74.4%
covid-19 33.3%
upper respiratory tract infection 17.8%
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
30 mg
headache 21.7%
nausea 18.3%
upper respiratory tract infection 13.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 26.4%
diarrhoea 13.2%
rash 11.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 31.9%
back pain 12.8%
oropharyngeal pain 12.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
headache 21.3%
diarrhoea 18%
nausea 18%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 21.8%
nausea 14.5%
bronchitis 10.9%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 27.5%
anxiety 11.8%
sinusitis 11.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
nausea 23.3%
headache 21.7%
diarrhoea 16.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
upper respiratory tract infection 17.3%
depression 9.6%
diarrhoea 9.6%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
diarrhoea 13%
nasopharyngitis 10.9%
gonorrhoea 8.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
dizziness 37.5% (placebo 0%)
dyspepsia 25% (placebo 0%)
headache 25% (placebo 0%)
NCT00920426 · Phase 2 · registry result, not featured evidence
5 mg
abdominal pain 0% (placebo 0%)
abnormal dreams 0% (placebo 0%)
blood bilirubin increased 0% (placebo 50%)
NCT00920426 · Phase 2 · registry result, not featured evidence
30 mg
atrioventricular block first degree 7.7%
decreased appetite 7.7%
headache 7.7%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
aspartate aminotransferase increased 50%
blood creatine phosphokinase increased 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site nodule 55.6%
injection site erythema 44.4%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site haemorrhage 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 72.7%
injection site pain 72.7%
injection site induration 45.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site induration 100%
injection site pain 100%
injection site bruising 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 75%
headache 37.5%
injection site swelling 37.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
catheter site bruise 50%
injection site erythema 50%
injection site induration 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 94.4%
headache 77.8%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 100%
injection site pruritus 87.5%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
injection site erythema 100%
injection site pain 100%
injection site warmth 88.9%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
accident 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site swelling 70%
headache 60%
NCT04484337 · Phase 1 · registry result, not featured evidence
30 mg
blood creatine phosphokinase increased 6.7%
contusion 6.7%
body temperature increased 0%
NCT03149848 · Phase 1 · registry result, not featured evidence
300 mg + 30 mg
body temperature increased 7.1%
headache 7.1%
hyperkeratosis 7.1%
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
25 mg DVR inserted once every 4 weeksa
metrorrhagia 55.1% (placebo 55.6%)
genitourinary chlamydia infection 20.5% (placebo 20.8%)
menorrhagia 19.7% (placebo 18.4%)
NCT01617096 · Phase 3 · monotherapy
show 9 more results
25 mg
infections 49.1%
reproductive system 20.9%
headache 3.5%
NCT02862171 · Phase 3
25 mg vaginal matrix ring
genitourinary chlamydia infection 8.4%
vaginal discharge 8%
vulvovaginitis trichomonal 5.9%
NCT02858037 · Phase 3 · registry result, not featured evidence
any event in soc 58.5%
any event in soc 32.4%
creatinine renal clearance decreased 30.3%
NCT03593655 · Phase 2 · registry result, not featured evidence
metrorrhagia 20.5% (placebo 26.1%)
vaginal discharge 15.1% (placebo 34.8%)
bacterial vaginosis 12.3% (placebo 8.7%)
NCT02028338 · Phase 2 · registry result, not featured evidence
vaginal discharge 11.1% (placebo 12.5%)
upper respiratory tract infection 8.3% (placebo 12.5%)
vaginal odour 6.9% (placebo 0%)
NCT02010593 · Phase 2 · registry result, not featured evidence
vaginitis bacterial 16.3% (placebo 11.9%)
vaginal candidiasis 9.3% (placebo 0%)
abdominal pain lower 4.7% (placebo 0%)
NCT00799058 · Phase 1/2 · registry result, not featured evidence
vaginitis bacterial 34.9% (placebo 11.9%)
vulvovaginal pruritus 9.3% (placebo 4.8%)
headache 7% (placebo 7.1%)
NCT00799058 · Phase 1/2 · registry result, not featured evidence
diarrhoea 11.1% (placebo 22.2%)
insomnia 11.1% (placebo 0%)
anal pruritus 5.6% (placebo 0%)
NCT03239483 · Phase 1 · registry result, not featured evidence
gynaecological chlamydia infection 32.7% (placebo 32.7%)
metrorrhagia 27% (placebo 29.6%)
genital infection female 23% (placebo 19.3%)
NCT01539226 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cabotegravir/rilpivirine (Cabenuva)

HIV-1 RNA Less Than 50 Copies Per 100% (n=93) @ 4wk400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
99% (n=93) @ 8wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
90% (n=93) @ 12wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
HIV-1 RNA Ge50 Copies 0% (n=93) @ 4wk400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
1.1% (n=93) @ 8wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
2.2% (n=93) @ 12wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
Virologic Failure 0% (n=93)400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
0% (n=115)
NCT04001803 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 99% (n=430) @ 4.33wk
responder rate · % of participants
No placebo or comparator arm
NCT04399551 · Phase 3 · registry result, not featured evidence
show 4 more results
96% (n=430) @ 8.67wk
NCT04399551 · Phase 3 · registry result, not featured evidence
93% (n=430) @ 17.33wk
NCT04399551 · Phase 3 · registry result, not featured evidence
86% (n=430) @ 34.67wk
NCT04399551 · Phase 3 · registry result, not featured evidence
87% (n=430) @ 52wk
NCT04399551 · Phase 3 · registry result, not featured evidence
Virologic Failure 0% (n=430) @ 4.33wk
event count · % of participants
No placebo or comparator arm
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 6 more results
0% (n=430) @ 8.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 17.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 26wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 34.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0.2% (n=430) @ 43.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
0% (n=430) @ 52wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
HIV-1 RNA LT 50 Copies 93.9% (n=115) @ 4.33wk
responder rate · % of participants
No placebo or comparator arm
NCT04001803 · Phase 3 · registry result, not featured evidence
show 25 more results
94.8% (n=115) @ 8.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
91.3% (n=115) @ 17.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
90.4% (n=115) @ 26wk
NCT04001803 · Phase 3 · registry result, not featured evidence
88.7% (n=115) @ 34.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
87.8% (n=115) @ 43.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
88.7% (n=115) @ 52wk
NCT04001803 · Phase 3 · registry result, not featured evidence
96% (n=115) @ 4.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 8.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
98% (n=115) @ 17.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 26wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 34.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
99% (n=115) @ 43.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 52wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 56.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 65wk
NCT04001803 · Phase 3 · registry result, not featured evidence
99% (n=115) @ 69.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 78wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 82.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 91wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 95.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 104wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 108.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 117wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 121.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 130wk
NCT04001803 · Phase 3 · registry result, not featured evidence
Virologic Failure 0.07 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.04 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Treatment Failure 0.14 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.2 Cumulative probability @ 44wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 0.13 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.12 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 9.9% (n=71) @ 44wk
event count · % of participants
No placebo or comparator arm
HIV-1 RNA ≥ 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
Virologic Response 50 Copies Snapshot 81.7% (n=71) @ 44wk
responder rate · % of participants
No placebo or comparator arm
HIV-1 RNA < 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 58 Participants as posted
HIV-1 RNA Less Than 50 Copies 94% (n=115) vs 91% (n=56) CAB 30 mg+ABC/3TC @ 32wkIM-Q4W
responder rate · % of participants
Maintenance
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 125 more results
95% (n=115) vs 91% (n=56) CAB 30 mg+ABC/3TC @ 32wkIM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
80% (n=60) vs 71% (n=62) Efavirenz @ 48wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=60) vs 74% (n=62) Efavirenz @ 24wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=60) vs 66% (n=62) Efavirenz @ 26wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
78% (n=60) vs 69% (n=62) Efavirenz @ 28wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=60) vs 69% (n=62) Efavirenz @ 32wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
82% (n=60) vs 71% (n=62) Efavirenz @ 36wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
82% (n=60) vs 68% (n=62) Efavirenz @ 40wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=60) vs 71% (n=62) Efavirenz @ 48wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
73% (n=60) vs 68% (n=62) Efavirenz @ 60wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
73% (n=60) vs 68% (n=62) Efavirenz @ 72wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=60) vs 68% (n=62) Efavirenz @ 84wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=60) vs 63% (n=62) Efavirenz @ 96wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
72% (n=60) vs 0% (n=62) Efavirenz @ 108wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
73% (n=60) vs 0% (n=62) Efavirenz @ 120wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
70% (n=60) vs 0% (n=62) Efavirenz @ 132wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
67% (n=60) vs 0% (n=62) Efavirenz @ 144wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
63% (n=60) vs 0% (n=62) Efavirenz @ 156wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
65% (n=60) vs 0% (n=62) Efavirenz @ 168wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
67% (n=60) vs 0% (n=62) Efavirenz @ 180wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
65% (n=60) vs 0% (n=62) Efavirenz @ 192wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 204wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
63% (n=60) vs 0% (n=62) Efavirenz @ 216wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
63% (n=60) vs 0% (n=62) Efavirenz @ 228wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 240wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 252wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 264wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 276wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 288wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
60% (n=60) vs 0% (n=62) Efavirenz @ 300wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 312wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
94% (n=53) vs 96% (n=47) Efavirenz @ 24wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=53) vs 87% (n=47) Efavirenz @ 26wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
89% (n=53) vs 91% (n=47) Efavirenz @ 28wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
91% (n=53) vs 91% (n=47) Efavirenz @ 32wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
92% (n=53) vs 94% (n=47) Efavirenz @ 36wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
92% (n=53) vs 89% (n=47) Efavirenz @ 40wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
91% (n=53) vs 94% (n=47) Efavirenz @ 48wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=53) vs 89% (n=47) Efavirenz @ 60wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=53) vs 89% (n=47) Efavirenz @ 72wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=53) vs 89% (n=47) Efavirenz @ 84wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=53) vs 83% (n=47) Efavirenz @ 96wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=61) vs 71% (n=62) Efavirenz @ 48wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=61) vs 74% (n=62) Efavirenz @ 24wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 66% (n=62) Efavirenz @ 26wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 69% (n=62) Efavirenz @ 28wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=61) vs 69% (n=62) Efavirenz @ 32wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 71% (n=62) Efavirenz @ 36wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 68% (n=62) Efavirenz @ 40wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=61) vs 71% (n=62) Efavirenz @ 48wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 68% (n=62) Efavirenz @ 60wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 68% (n=62) Efavirenz @ 72wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 68% (n=62) Efavirenz @ 84wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
84% (n=61) vs 63% (n=62) Efavirenz @ 96wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=61) vs 0% (n=62) Efavirenz @ 108wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=61) vs 0% (n=62) Efavirenz @ 120wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=61) vs 0% (n=62) Efavirenz @ 132wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
77% (n=61) vs 0% (n=62) Efavirenz @ 144wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=61) vs 0% (n=62) Efavirenz @ 156wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 168wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 180wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
74% (n=61) vs 0% (n=62) Efavirenz @ 192wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 204wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
77% (n=61) vs 0% (n=62) Efavirenz @ 216wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 228wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
74% (n=61) vs 0% (n=62) Efavirenz @ 240wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 252wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 264wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
70% (n=61) vs 0% (n=62) Efavirenz @ 276wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
74% (n=61) vs 0% (n=62) Efavirenz @ 288wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
70% (n=61) vs 0% (n=62) Efavirenz @ 300wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
70% (n=61) vs 0% (n=62) Efavirenz @ 312wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=55) vs 96% (n=47) Efavirenz @ 24wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 87% (n=47) Efavirenz @ 26wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 91% (n=47) Efavirenz @ 28wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=55) vs 91% (n=47) Efavirenz @ 32wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 94% (n=47) Efavirenz @ 36wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 89% (n=47) Efavirenz @ 40wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=55) vs 94% (n=47) Efavirenz @ 48wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 89% (n=47) Efavirenz @ 60wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 89% (n=47) Efavirenz @ 72wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 89% (n=47) Efavirenz @ 84wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
93% (n=55) vs 83% (n=47) Efavirenz @ 96wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=60) vs 71% (n=62) Efavirenz @ 48wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=60) vs 74% (n=62) Efavirenz @ 24wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
78% (n=60) vs 66% (n=62) Efavirenz @ 26wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=60) vs 69% (n=62) Efavirenz @ 28wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=60) vs 69% (n=62) Efavirenz @ 32wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=60) vs 71% (n=62) Efavirenz @ 36wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=60) vs 68% (n=62) Efavirenz @ 40wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=60) vs 71% (n=62) Efavirenz @ 48wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
78% (n=60) vs 68% (n=62) Efavirenz @ 60wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
72% (n=60) vs 68% (n=62) Efavirenz @ 72wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
72% (n=60) vs 68% (n=62) Efavirenz @ 84wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
68% (n=60) vs 63% (n=62) Efavirenz @ 96wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
68% (n=60) vs 0% (n=62) Efavirenz @ 108wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
65% (n=60) vs 0% (n=62) Efavirenz @ 120wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 132wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
58% (n=60) vs 0% (n=62) Efavirenz @ 144wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
58% (n=60) vs 0% (n=62) Efavirenz @ 156wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
57% (n=60) vs 0% (n=62) Efavirenz @ 168wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
58% (n=60) vs 0% (n=62) Efavirenz @ 180wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
57% (n=60) vs 0% (n=62) Efavirenz @ 192wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
55% (n=60) vs 0% (n=62) Efavirenz @ 204wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
55% (n=60) vs 0% (n=62) Efavirenz @ 216wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
53% (n=60) vs 0% (n=62) Efavirenz @ 228wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
50% (n=60) vs 0% (n=62) Efavirenz @ 240wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 252wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
53% (n=60) vs 0% (n=62) Efavirenz @ 264wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 276wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
50% (n=60) vs 0% (n=62) Efavirenz @ 288wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 300wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 312wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=52) vs 96% (n=47) Efavirenz @ 24wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
90% (n=52) vs 87% (n=47) Efavirenz @ 26wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
98% (n=52) vs 91% (n=47) Efavirenz @ 28wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=52) vs 91% (n=47) Efavirenz @ 32wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
98% (n=52) vs 94% (n=47) Efavirenz @ 36wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=52) vs 89% (n=47) Efavirenz @ 40wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
92% (n=52) vs 94% (n=47) Efavirenz @ 48wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
90% (n=52) vs 89% (n=47) Efavirenz @ 60wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=52) vs 89% (n=47) Efavirenz @ 72wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=52) vs 89% (n=47) Efavirenz @ 84wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
79% (n=52) vs 83% (n=47) Efavirenz @ 96wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
98% (n=90) vs 100% (n=7) DTG + RPV @ 48wkQ2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination

+ 172 further endpoints in the CSV export.

Dapivirine

HIV-1 Incidence Rate Per 100 PY 2.7 count @ 56.5wk25 mg vaginal matrix ring
event rate · count
No placebo or comparator arm
NCT02858037 · Phase 3 · registry result, not featured evidence
HIV-2 Seroconversion 0% (n=1302) vs 0% (n=650) placebo @ 104wk
event count · % of participants
Maintenance
NCT01539226 · Phase na · registry result, not featured evidence · converted to % from 0 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir/rilpivirine (Cabenuva)'s landscape · Dapivirine's landscape